Empirical treatment of liposomal amphotericin B for febrile neutropenia. that persists despite broad-spectrum antibacterial therapy

Empirical treatment of liposomal amphotericin B for febrile neutropenia. that persists despite broad-spectrum antibacterial therapy - Empiric L-AMB treatment for FN

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005163

Enrollment

Registered

2011-03-01

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

febrile neutropenia

Interventions

Empirical therapy of L-AMB

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with haematological malignancies accompanied by febrile neutropenia who do not respond to antibiotics after 3~5 days. Patients who cannot expect recovery of the neutrophile immediately.

Exclusion criteria

Exclusion criteria: (1) Allergy to L-AMB (2) Renal failure (3) Allergy to soy bean (4) Patients with WBC transfusion (5) Those considered inappropriate to be participated

Design outcomes

Primary

Measure	Time frame
Successful treatment of any baseline fungal infection, absence of any breakthrough fungal infection during therapy or within seven days after the completion of therapy, survival for seven days after the completion of therapy, no premature discontinuation of study therapy because of drug-related toxicity or lack of efficacy, and resolution of fever during neutropenia.	—

Secondary

Measure	Time frame
Evaluation of the validity of the criteria. To clarify the relationship between blood concentration of L-AMB and effectiveness or toxicity.	—

Countries

Japan

Contacts

Public ContactSatoshi Ikegaya

University of Fukui The first department of internal medicine

sikegaya@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026